Balyasny Asset Management LLC Cyma Bay Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $7.5 Million - $12.2 Million	-690,679 Reduced 40.28%	1,024,139 $15.3 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.81 Million - $2.65 Million	-242,250 Reduced 12.38%	1,714,818 $18.8 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $11.2 Million - $18.2 Million	1,901,769 Added 3439.07%	1,957,068 $17.1 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $178,062 - $346,724	55,299 New	55,299 $346,000
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $410,951 - $578,703	-80,264 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $163,452 - $369,052	27,017 Added 50.74%	80,264 $575,000
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $1.56 Million - $2.56 Million	-190,819 Reduced 78.18%	53,247 $707,000
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $1.6 Million - $2.87 Million	244,066 New	244,066 $1.92 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.